Précis: Heterogeneity of actionable genomic alterations among primary and metastatic lesions suggests that biomarker profiling of a single primary tumor site may limit the success of targeted therapy in gastroesophageal adenocarcinoma .
To determine how melanomas that have adapted and become addicted to MAPK inhibitors (MAPKi) respond to MAPKi withdrawal, Hong, Moriceau, and colleagues characterized the phenotypes of MAPKi-resistant melanoma cell lines after drug withdrawal . MAPKi-resistant cell lines exhibited either a cell death-predominant drug addiction phenotype characterized by ERK hyperactivation and DNA damage, or a slow cycling-predominant drug addiction phenotype . DNA damage-induced PARP1-dependent cell death was essential for the cell death-predominant phenotype, and DNA damage repair inhibitors such as PARPi induced apoptosis in cell death-predominant melanoma cell lines and caused slow cycling-predominant melanoma cell lines to switch to a cell deathpredominant phenotype . Combined PARPi and vemurafenib treatment induced MAPKi-addicted tumor regression after MAPKi withdrawal . These findings identify a therapeutically exploitable mechanism driving MAPKi addiction in melanoma . For details, please see the article by Hong, Moriceau, and colleagues on page 74 .
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